| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 05/06/2004 | EP1414447A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 05/06/2004 | EP1414443A1 BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES |
| 05/06/2004 | EP1414439A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 05/06/2004 | EP1268407B1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 05/06/2004 | EP1257548B1 Benzofuran carboxamides and their therapeutic use |
| 05/06/2004 | EP1060181B1 Substituted pyrrolobenzimidazoles for treating inflammatory diseases |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2500490A1 Neutralizing antibodies against gdf-8 and uses therefor |
| 05/05/2004 | CN1494542A 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 05/05/2004 | CN1148367C Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same |
| 05/05/2004 | CN1148357C Triazole derivative |
| 05/04/2004 | US6730676 Central nervous system disorders; cognition activators |
| 04/29/2004 | WO2004035070A1 Induction of gene expression using a high concentration sugar mixture |
| 04/29/2004 | WO2004035053A1 Neurotrophic factor production promoter |
| 04/29/2004 | WO2004035011A2 Botulinum toxin dental therapies and procedures |
| 04/29/2004 | WO2004019868A3 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 04/29/2004 | WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 04/29/2004 | WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | WO2001082953A8 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 04/29/2004 | WO1999028440A9 Nucleic acid encoding mammalian ubr1 |
| 04/29/2004 | US20040082798 Novel amino dicarboxylic acid derivatives with pharmaceutical properties |
| 04/29/2004 | US20040082790 Piperidine amides as modulators of chemokine receptor activity |
| 04/29/2004 | US20040082789 Thieno[2,3-c]iosquinolines for use as inhibitors of parp |
| 04/29/2004 | US20040082781 Bicyclic nitrogenous fused-ring compound |
| 04/29/2004 | US20040082664 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 04/29/2004 | US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders |
| 04/29/2004 | US20040082499 Perturbed membrane-binding compounds |
| 04/29/2004 | US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents |
| 04/29/2004 | US20040081693 Capable of releasing the drug at a constant rate following zero order kinetics for 24 hours or more |
| 04/29/2004 | US20040081624 Mixture containing high volatility carrier; vaporization; mixing with air |
| 04/29/2004 | CA2501856A1 Botulinum toxin dental therapies and procedures |
| 04/29/2004 | CA2500417A1 Neurotrophic factor production promoter |
| 04/29/2004 | CA2498213A1 Induction of gene expression using a high concentration sugar mixture |
| 04/28/2004 | EP1413299A2 Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function |
| 04/28/2004 | EP1413295A1 Sustained release composition for oral administration of drugs |
| 04/28/2004 | EP1412374A2 Novel pgc-1 isoforms and uses therefor |
| 04/28/2004 | EP1412330A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/28/2004 | EP1412327A2 Inhibitors of protein kinase for the treatment of disease |
| 04/28/2004 | EP1411970A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 04/28/2004 | EP1411966A2 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 04/28/2004 | EP1411961A1 Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia |
| 04/28/2004 | EP1411957A1 Treatment of muscular distrophy with cord blood cells |
| 04/28/2004 | EP1411898A1 Pharmaceutical composition comprising lipids with a polar and a nonpolar moiety |
| 04/28/2004 | EP1037539B1 Method for accelerating protein digestion rate and modified protein product |
| 04/28/2004 | EP0885309B1 Direct molecular diagnosis of friedreich ataxia |
| 04/28/2004 | CN1492737A Functional agent for decomposing nicotine and method of preparing the same |
| 04/28/2004 | CN1147461C 3-amino-3-aryl-1-alcohol derivatives and preparation and use thereof |
| 04/28/2004 | CA2447199A1 Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
| 04/28/2004 | CA2447167A1 Homing of autologous cells to a target zone in tissue using active therapeutics or substances |
| 04/27/2004 | US6727355 Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| 04/27/2004 | US6727279 Central nervous system disorders |
| 04/27/2004 | US6727275 Pyrrolidinone derivatives |
| 04/27/2004 | US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 04/27/2004 | US6727231 Effective to improve one or more of the symptoms of autistic disorder |
| 04/27/2004 | US6727226 Conotoxin peptide extracted from the venom of a marine snail, conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics |
| 04/22/2004 | WO2004033674A1 Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances |
| 04/22/2004 | WO2004009784A3 Novel inhibitors of kinases |
| 04/22/2004 | WO2003070965A8 The eaat2 promoter and uses thereof |
| 04/22/2004 | WO2003068937A3 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 04/22/2004 | WO2003027248A8 Antibody inhibitors of gdf-8 and uses thereof |
| 04/22/2004 | WO2002098857A8 New indole derivatives with 5-ht6 receptor affinity |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077828 Proteins containing the motif that are capable of binding to secreted Frizzled-related protein (Sfrp) family members |
| 04/22/2004 | US20040077719 Food supplements, feed additives, dietetic, cosmetics |
| 04/22/2004 | US20040077702 Administering indazole derivative; or thienyl-, furyl-, or pyrrolyl- fused pyrazole derivative to treat Alzheimer*s, Parkinson*s, or Huntington*s disease |
| 04/22/2004 | US20040077681 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 04/22/2004 | US20040077667 Quinazolinone derivatives |
| 04/22/2004 | US20040077657 HT3 Receptor antagonists; amyotrophic lateral sclerosis, premenstrual tension, obsessive-compulsive disorder; Parkinson*s, Alzheimer*s, and Huntington*s disease; memory, eating, psychological, and nervous system disorders |
| 04/22/2004 | US20040077614 High, sustained blood concentration levels even during pregnacy without hepatic side effects; 3,17-dipropionate or dihexanoate; multiple sclerosis |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/21/2004 | EP1410800A1 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts |
| 04/21/2004 | EP1410797A1 Solid oral dosage forms comprising valsartan |
| 04/21/2004 | EP1410796A2 New therapeutic uses for potassium channel openers |
| 04/21/2004 | EP1410034A2 Methods and compositions for the treatment and prevention of smooth muscle cell proliferation |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409680A2 Novel human proton-gated channels |
| 04/21/2004 | EP1409679A2 Nov-x proteins and nucleic acids encoding same |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409539A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409489A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 04/21/2004 | EP1409477A1 Piperidine derivatives as nmda receptor antagonists |
| 04/21/2004 | EP1409015A1 Methods for treating or preventing skin disorders using cd2-binding agents |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409000A4 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1409000A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1105370B1 Novel aryl sulphonamides and analogues |
| 04/21/2004 | CN1146455C 1,2,4,5-tetrahydro-benzo[d] azepine compound |
| 04/21/2004 | CN1146441C Composition of containing lympha toxin beta receptor |
| 04/20/2004 | US6723741 Benzimidazoles and benzothiazoles and uses thereof |
| 04/20/2004 | US6723736 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (tnf-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (cox-2) |
| 04/20/2004 | US6723552 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| 04/15/2004 | WO2004005309A3 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 04/15/2004 | WO2003082893A3 Theraputic methods and uses of sapogenins and their derivatives |
| 04/15/2004 | WO2003049723A8 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity |
| 04/15/2004 | WO2003004604A9 Phage displayed pdz domain ligands |